Publication | Closed Access

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Hematological MalignancyThrombosisTranslational MedicineBone Marrow FailureBlood TransfusionHematologyClinical TrialsPathologyPrimary AnalysisMyelopoiesisLower-risk Myelodysplastic SyndromesMedicineCell TransplantationAplastic AnemiaPhase 3Health Sciences